CN101812058B - Indometacin 2-arylmorpholine ethyl, preparation method and application thereof - Google Patents

Indometacin 2-arylmorpholine ethyl, preparation method and application thereof Download PDF

Info

Publication number
CN101812058B
CN101812058B CN2010101449965A CN201010144996A CN101812058B CN 101812058 B CN101812058 B CN 101812058B CN 2010101449965 A CN2010101449965 A CN 2010101449965A CN 201010144996 A CN201010144996 A CN 201010144996A CN 101812058 B CN101812058 B CN 101812058B
Authority
CN
China
Prior art keywords
indomethacin
ethyl
arylmorpholine
indometacin
morpholinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101449965A
Other languages
Chinese (zh)
Other versions
CN101812058A (en
Inventor
胡艾希
石磊
徐江平
叶姣
蒋毅萍
林焕冰
周溪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan University
Original Assignee
Hunan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan University filed Critical Hunan University
Priority to CN2010101449965A priority Critical patent/CN101812058B/en
Publication of CN101812058A publication Critical patent/CN101812058A/en
Application granted granted Critical
Publication of CN101812058B publication Critical patent/CN101812058B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses indometacin 2-arylmorpholine ethyl or a salt thereof has a structural formula in the specification. The preparation method for the indometacin 2-arylmorpholine ethyl (I) comprises the following steps: dissolving indometacin chloride into tetrahydrofuran to obtain solution; adding the solution of 4-hydroxyethyl-2-arylmorpholine tetrahydrofuran into the solution dropwise with stirring; and after finishing reaction, distilling for recovering the tetrahydrofuran so as to obtain the indometacin 2-arylmorpholine ethyl. The preparation method for the salt of the indometacin 2-arylmorpholine ethyl comprises the following steps: dissolving the indometacin 2-arylmorpholine ethyl into absolute ethyl ether or ethanol; and introducing dry HCl gas or performing a reaction with acid (HY) to obtain the salt of the indometacin 2-arylmorpholine ethyl (II). The indometacin 2-arylmorpholine ethyl or the salt thereof is applied to preparing anti-inflammatory analgesics.

Description

Indometacin 2-arylmorpholine ethyl and preparation method thereof and application
Technical field
The present invention relates to one type of new compound, specifically is Indometacin 2-arylmorpholine ethyl or its salt.
Background technology
Traditional non-steroid antiinflammatory drug (non-steroidal anti-inflammatory drugs; NSAIDs) COX-1 and COX-2 there is restraining effect; Effective therapeutic action of NSAIDs comes from its inhibition to COX-2, and untoward reaction belongs to the inhibition to COX-1.The whole world has 3,000 ten thousand to 4,000 ten thousand patient taking NSAIDs the every day, and annual untoward reaction that is caused by this type medicine or complication be up to 200,000 examples, wherein case fatality rate＞20%.The untoward reaction of NSAIDs appears clinically.
Traditional non-steroid antiinflammatory drug suppresses cyclooxygenase-1 (COX-1) and COX-2 simultaneously, and gastrointestinal side effect is arranged.By comparison, the COX-2 selective depressant keeps anti-inflammatory and analgesia effect, but avoids or reduced GI toxic side effect.The difference of COX-2 and COX-1 structure is the basis of designs C OX-2 selective depressant; The volume ratio COX-1 in COX-2 catalytic activity chamber is big by about 25%; And have the unexistent side of a COX-1 pocket, this mainly is because the difference of a key amino acid residue causes.Yang Cuifen etc. have described with compounds such as indomethacin and halohydrocarbon, nitrobenzyl alcohol, nitrobenzyl chlorides and have carried out condensation and nitric acid esterification, prepare 4 kinds of indomethacin verivates.Its antiphlogistic activity apparently higher than indomethacin (Chinese Journal of New Drugs, 2004,13:818-820).Can improve the selectivity that COX-2 is suppressed through traditional non-steroid antiinflammatory drug being carried out structure of modification, design the compound (A, Bioorg.Med.Chem.Lett.2001,11,1325) that will be replaced by substituted thiazolyl the indomethacin carboxyl.Structural modification be the anti-ester of indomethacin (B, Bioorg.Med.Chem.2005,13:6810-6822) with the indomethacin phenethyl ester (C, Journal of Medicinal Chemistry, 2000,43:2860-2870).The Preliminary pharmacological test result of this analog derivative shows that compound is able to keep to the restraining effect of COX-2 after transforming, and the restraining effect of COX-1 is disappeared, and has strengthened the selectivity that COX-2 is suppressed.
Figure GSA00000080284500011
The structure activity relationship that the present invention is based on non-steroid antiinflammatory drug is carried out structural modification to its carboxyl, in indomethacin phenethyl ester (C) structure, introduces morpholinyl, and indomethacin is designed to Indometacin 2-arylmorpholine ethyl (I).Expectation compound I and II and phenylbenzene substituted pyrazolecarboxylic ring (three a rings) type celecoxib (Celecoxib) has similar biological activity.
Summary of the invention
The object of the present invention is to provide Indometacin 2-arylmorpholine ethyl or its salt.It is characterized in that it has following chemical structural formula:
Wherein, R is selected from: hydrogen, C 1～C 4Alkyl; Ar is selected from: phenyl, 2-chloro-phenyl-, 3-chloro-phenyl-, 4-chloro-phenyl-, 3,4-dichlorophenyl, 3; The 5-dichlorophenyl, 2,4 dichloro benzene base, 2,6-dichlorophenyl, 2,4-two chloro-5-fluorophenyls; 2-(trifluoromethyl) phenyl, 3-(trifluoromethyl) phenyl, 4-(trifluoromethyl) phenyl, 3,5-two (trifluoromethyl) phenyl, 2-aminomethyl phenyl, 3-aminomethyl phenyl; The 4-aminomethyl phenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-p-methoxy-phenyl, 3-p-methoxy-phenyl, 4-p-methoxy-phenyl; The 2-ethoxyl phenenyl, 3-ethoxyl phenenyl, 4-ethoxyl phenenyl, 3-isopropyl phenyl, 4-isopropyl phenyl, 3-isopentyloxy phenyl; 4-isopentyloxy phenyl, 3-benzyloxy phenyl, 4-benzyloxy phenyl, 4-methanesulfonamido phenyl, 4-sulfamoyl phenyl, 3; The 4-Dimethoxyphenyl, 3,5-Dimethoxyphenyl, 6-methoxyl group-2-naphthyl, 6-methoxyl group-5-chloro-2-naphthyl, 6-methoxyl group-5-bromo-2-naphthyl.HY is selected among the formula II: HCl, HBr, H 3PO 4, H 2SO 4, CH 3SO 3H, p-CH 3C 6H 4SO 3H.
The present invention also aims to provide chemistry 2-methyl isophthalic acid by name-(4-chlorobenzene formacyl)-5-methoxyl group-indole-3-acetic acid 2-(2-aryl morpholine base) ethyl ester of said Indometacin 2-arylmorpholine ethyl.
The present invention also aims to provide the preparation method of said Indometacin 2-arylmorpholine ethyl (I); It is characterized in that the indomethacin acyl chlorides is dissolved in the THF; Stir and drip the 2-aryl-4-hydroxyethyl morpholine tetrahydrofuran solution that is equivalent to 1～2 times of molar weight of indomethacin acyl chlorides down; Reaction finishes, and THF is reclaimed in distillation, and the oily matter that obtains gets Indometacin 2-arylmorpholine ethyl through column chromatography.
The present invention also aims to provide said indomethacin acyl chlorides preparation method; It is characterized in that the acid of indomethacin acid indomethacin is dissolved in the solvent, add the chlorizating agent that is equivalent to 1～4 times of molar weight of indomethacin acid consumption, stir and drip catalyst n; Dinethylformamide; Refluxed 5～8 hours, vacuum distillation recovered solvent gets solid, promptly gets the indomethacin acyl chlorides after the washing.
The present invention also aims to provide the preparation method of said Indometacin 2-arylmorpholine ethyl salt (II); It is characterized in that Indometacin 2-arylmorpholine ethyl is dissolved in anhydrous diethyl ether or ethanol; Feed dry HCl gas or with respective acids reaction, obtain Indometacin 2-arylmorpholine ethyl salt.
Indometacin 2-arylmorpholine ethyl preparation method of the present invention is undertaken by following reaction formula:
Figure GSA00000080284500031
The preparation method of Indometacin 2-arylmorpholine ethyl salt is undertaken by following reaction formula:
Figure GSA00000080284500032
HY＝HCl，HBr，H 3PO 4，H 2SO 4，CH 3SO 3H，p-CH 3C 6H 4SO 3H
The present invention also aims to provide said Indometacin 2-arylmorpholine ethyl or the application of its salt in pharmacy.Described Indometacin 2-arylmorpholine ethyl or its salt have inhibition cyclooxygenase-2 (COX-2) active function, are used to prepare anti-inflammation and analgesic drugs.
The present invention compared with prior art has following advantage:
1, the present invention introduces morpholinyl in indomethacin phenethyl ester structure, and indomethacin is transformed into the Indometacin 2-arylmorpholine ethyl new compound.
Figure GSA00000080284500033
2, the structure activity relationship that the present invention is based on non-steroid antiinflammatory drug is carried out structural modification to its carboxyl, on the morpholine ring, introduces aryl, is designed to Indometacin 2-arylmorpholine ethyl (I or II).Compound I or II and phenylbenzene substituted pyrazolecarboxylic ring (three a rings) type celecoxib (Celecoxib) has similar biological activity.
3, traditional non-steroid antiinflammatory drug such as indomethacin are transformed into the COX-2 selective depressant.Utilized Autodock process simulation indomethacin acid and COX-1 and COX-2 bonded conformation; And compare with the structure of COX-2 selective depressant SC-558 and COX-2 crystalline complex; Find indomethacin acid heat to occupy the structure fragment of COX-2 side pocket; Cause two isozyme non-selectivities are designed to Indometacin 2-arylmorpholine ethyl with indomethacin thus, in the hope of occupying the side pocket of COX-2; Increase obtains the COX-2 selective depressant the keying action of COX-2.
Embodiment
Following examples are intended to explain the present invention rather than to further qualification of the present invention.
The preparation of embodiment 1 indomethacin 2-(2-phenylmorpholine base) ethyl ester and hydrochloride thereof
(1) preparation of indomethacin acyl chlorides
The 3mmol indomethacin is dissolved in the 8mL methylene dichloride, adds the 1mL oxalyl chloride, and ice bath stirs 3h, removes solvent under reduced pressure, separates remaining oxalyl chloride, gets yellow solid indomethacin acyl chlorides.
(2) preparation of indomethacin 2-(2-phenylmorpholine base) ethyl ester and hydrochloride thereof
Figure GSA00000080284500041
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-phenyl-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-(2-phenylmorpholine base) ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-(2-phenylmorpholine base) ethyl ester, feed dry hydrogen chloride and get indomethacin 2-(2-phenylmorpholine base) carbethoxy hydrochloride, yield 72%, fusing point: 184～186 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 2.35 (s, 3H, CH 3), 2.61 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21 (bm, 2H, NCH 2), 3.35 (d, J=12Hz, 1H, C 4H 7NO 5-He), 3.49 (d, J=11.2Hz, 1H, C 4H 7NO 3-He), 3.80 (s, 2H, OCH 2), 3.85 (s, 3H, OCH 3), 3.93 (d, J=11.2Hz, 1H, C 4H 7NO 6-Ha), 4.38 (t, J=12.8Hz, 1H, C 4H 7NO 6-He), 4.68 (s, 2H, CH 2CO), 5.24 (d, J=10Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 12H, C 6H 5, C 6H 4, C 6H 3), 13.76 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 2 indomethacin 2-[2-(4-aminomethyl phenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500042
Figure GSA00000080284500051
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(4-aminomethyl phenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(4-aminomethyl phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(4-aminomethyl phenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(4-aminomethyl phenyl) morpholinyl] carbethoxy hydrochloride, yield 49%, fusing point: 170～172 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), 6:2.33 (s, 3H, phenyl ring CH 3), 2.35 (s, 3H, indole ring CH 3), 2.59 (br, 2H, C 4H 7NO 3,5-Ha), and 3.20 (bm, 2H, NCH 2), 3.34 (d, J=12.4Hz, 1H, C 4H 7NO 5-He), 3.46 (d, J=12Hz, 1H, C 4H 7NO 3-He), 3.80 (s, 2H, OCH 2), 3.85 (s, 3H, OCH 3), 3.91 (dd, J=3.2Hz, J=3.2Hz, 1H, C 4H 7NO 6-Ha), 4.38 (t, J=12.0Hz, 1H, C 4H 7NO6-He), 4.68 (s, 2H, CH 2CO), 5.19 (d, J=9.2Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 11H, C 6H 5, C 6H 4, C 6H 3), 13.72 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 3 indomethacin 2-[2-(4-ethylphenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500052
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(4-ethylphenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(4-ethylphenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(4-ethylphenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(4-ethylphenyl) morpholinyl] carbethoxy hydrochloride, yield 22%, fusing point: 186～189 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 1.21 (t, J=7.6Hz, 3H, CH 3), 2.35 (s, 3H, indoles 2-CH 3), 2.58～2.68 (m, 4H, PhCH 2, C 4H 7NO 3,5-Ha), and 3.22 (bm, 2H, NCH 2), 3.35 (d, J=10.8Hz, 1H, C 4H 7NO 5-He), 3.48 (d, J=10.8Hz, 1H, C 4H 7NO 3-He), 3.80 (s, 2H, OCH 2), 3.85 (s, 3H, OCH 3), 3.91 (d, J=12.4Hz, 1H, C 4H 7NO 6-Ha), 4.38 (t, J=12.4Hz, 1H, C 4H 7NO 6-He), 4.68 (s, 2H, CH 2CO), 5.20 (d, J=10.8Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 11H, C 6H 5, C 6H 4, C 6H 3), 13.69 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 4 indomethacin 2-[2-(4-p-methoxy-phenyl) morpholinyl] ethyl ester and hydrochloride thereof
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(4-p-methoxy-phenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(4-p-methoxy-phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(4-p-methoxy-phenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(4-p-methoxy-phenyl) morpholinyl] carbethoxy hydrochloride, yield 47%, fusing point: 185～187 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 2.36 (s, 3H, CH 3), 2.59 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21 (br, 2H, NCH 2), 3.34 (d, J=11.2Hz, 2H, C 4H 7NO 5-He), 3.44 (d, J=11.2Hz, 2H, C 4H 7NO 3-He), 3.80 (s, 2H, OCH 2), 3.81 (s, 3H, phenyl ring OCH 3), 3.85 (s, 3H, indole ring OCH 3), 3.91 (d, J=11.6Hz, 1H, C 4H 7NO 6-Ha), 4.38 (t, J=8.8Hz, 1H, C 4H 7NO 6-He), 4.68 (s, 2H, CH 2CO), 5.17 (d, J=10.4Hz, 1H, C 4H 7NO 2-H), 6.86～7.68 (m, 11H, C 6H 4, C 6H 4, C 6H 3), 13.67 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 5 indomethacin 2-[2-(4-isopropyl phenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500071
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(4-isopropyl phenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(4-isopropyl phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(4-isopropyl phenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(4-isopropyl phenyl) morpholinyl] carbethoxy hydrochloride, yield 57%, fusing point: 218～219 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 1.32 (d, J=6Hz, 6H, 2CH 3), 2.37 (s, 3H, CH 3), 2.61 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21 (br, 2H, NCH 2), 3.33 (d, J=11.2Hz, 2H, C 4H 7NO 5-He), 3.44 (d, J=11.6Hz, 2H, C 4H 7NO 3-He), 3.81 (s, 2H, OCH 2), 3.85 (s, 3H, OCH 3), 3.90 (dd, J=2.8Hz, J=2.8Hz, 1H, C 4H 7NO 6-Ha), 4.37 (t, J=12.4Hz, 1H, C 4H 7NO 6-He), 4.53 (7 heavy peaks, 1H, (CH 3) 2CHO), 4.68 (s, 2H, CH 2CO), 5.15 (d, J=10.8Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 11H, C 6H 5, C 6H 4, C 6H 3), 13.69 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 6 indomethacin 2-[2-(4-butoxy phenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500072
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(4-butoxy phenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(4-butoxy phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(4-butoxy phenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(4-butoxy phenyl) morpholinyl] carbethoxy hydrochloride, yield 46%, fusing point: 179～180 ℃.Proton nmr spectra structural characterization data: 1HNMR (CDCl 3, 400MHz), δ: 0.97 (t, J=6.8Hz, 3H, CH 3(CH 2) 3), 1.48 (6 heavy peaks, 2H, CH 3CH 2), 1.75 (5 heavy peaks, 2H, CH 3CH 2CH 2), 2.36 (s, 3H, CH 3), 2.60 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21 (br, 2H, NCH 2), 3.33 (d, J=12.0Hz, 1H, C 4H 7NO 5-He), 3.44 (d, J=11.6Hz, 1H, C 4H 7NO 3-He), 3.80 (s, 2H, C 3H 7CH 2O), 3.85 (s, 3H, indole ring OCH 3), 3.92 (s, 2H, OCH 2), 3.94 (d, J=10.8Hz, 1H, C 4H 7NO 6-Ha), 4.37 (t, J=12.4Hz, 1H, C 4H 7NO 6-He), 4.68 (s, 2H, CH 2CO), 5.15 (d, J=10.4Hz, 1H, C 4H 7NO 2-H), 6.68～7.22 (m, 11H, C 6H 4, C 6H 4, C 6H 3), 13.65 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 7 indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] ethyl ester and hydrochloride thereof
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 2-(2,4-two chloro-5-fluorophenyls)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters, and filtrating is through the removal of solvent under reduced pressure THF; With the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction gets organic layer; Steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] carbethoxy hydrochloride, yield 43%, fusing point: 171～174 ℃.Proton nmr spectra structural characterization data: 1H NMR (400MHz, CDCl 3), δ: 2.36 (s, 3H, CH 3), 2.59 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21～3.37 (m, 4H, C 4H 7NO 3,5-He, NCH 2), 3.81 (s, 2H, OCH 2), 3.85 (s, 3H, phenyl ring OCH 3), 3.95 (d, J=12Hz, 1H, C 4H 7NO 6-Ha), 4.45 (s, 1H, C 4H 7NO 6-He), 4.69 (s, 2H, CH 2CO), 5.52 (d, J=8.0Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 9H, C 6H 4, C 6H 3, C 6H 2), 14.06 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 8 indomethacin 2-[2-(2-chloro-4-(4-chlorophenoxy) phenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500091
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol [2-chloro-4-(4-chlorophenoxy)] phenyl-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF; With the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction gets organic layer; Steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(2-chloro-4-(4-chlorophenoxy) phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(2-chloro-4-(4-chlorophenoxy) phenyl) morpholinyl] ethyl ester; Feed dry hydrogen chloride and get indomethacin 2-[2-(2-chloro-4-(4-chlorophenoxy) phenyl) morpholinyl] carbethoxy hydrochloride; Yield 33%, fusing point: 166～168 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 2.36 (s, 3H, CH 3), 2.51 (br, 2H, C 4H 7NO 3,5-Ha), and 3.21 (br, 2H, NCH 2), 3.35 (d, J=10.4Hz, 1H, C 4H 7NO 5-He), 3.65 (d, J=12.8Hz, 1H, C 4H 7NO 3-He), 3.81 (s, 2H, OCH 2), 3.85 (s, 3H, indole ring OCH 3), 3.94 (d, J=12.4Hz, 1H, C 4H 7NO 6-Ha), 4.45 (t, J=11.6Hz, 1H, C 4H 7NO 6-He), 4.69 (s, 2H, CH 2CO), 5.53 (d, J=10.4Hz, 1H, C 4H 7NO 2-H), 6.68～7.68 (m, 14H, C 6H 4, C 6H 4, C 6H 3, C 6H 3), 14.03 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 9 indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500092
Figure GSA00000080284500101
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol (6-methoxyl group-2-naphthyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] carbethoxy hydrochloride, yield 30%, fusing point: 101～102 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 500MHz), δ: 2.36 (s, 3H, CH 3), 2.47 (br, 2H, C 4H 7NO3,5-Ha), 2.92～3.28 (m, 4H, NCH 2, C 4H 7NO 5-He, 3-He), 3.73 (s, 2H, OCH 2), 3.83 (s, 3H, indole ring CH 3O), 3.91 (s, 3H, naphthalene nucleus CH 3O), 3.97 (d, J=8Hz, 1H, C 4H 7NO 6-Ha), 4.01 (br, 1H, C 4H 7NO 6-He), 4.48 (s, 2H, CH 2CO), 4.91 (m, 3H, OCH 2, C 4H 7NO 2-H), 6.64～7.72 (m, 13H, C 10H 6, C 6H 4, C 6H 3), 13.49 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 10 indomethacin 2-[2-(5-chloro-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500102
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol (5-chloro-6-methoxyl group-2-naphthyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(5-chloro-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(5-chloro-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester; Feed dry hydrogen chloride and get indomethacin 2-[2-(5-chloro-6-methoxyl group-2-naphthyl) morpholinyl] carbethoxy hydrochloride; Yield 45%, fusing point: 229～230 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 2.37 (s, 3H, CH 3), 2.66 (br, 2H, C 4H 7NO 3,5-Ha), and 3.31～3.55 (bm, 4H, NCH 2, C 4H 7NO 5-He, 3-He), 3.81 (s, 2H, OCH 2), 3.85 (s, 3H, indole ring CH 3O), 3.99 (br, 1H, C 4H 7NO 6-Ha), 4.05 (s, 3H, naphthalene nucleus CH 3O), 4.46 (br, 1H, C 4H 7NO 6-He), 4.71 (br, 2H, CH 2CO), 5.44 (br, 1H, C 4H 7NO 2-H), 6.68～8.22 (m, 12H, C 10H 5, C 6H 4, C 6H 3), 13.78 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 11 indomethacin 2-[2-(5-bromo-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500111
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol (5-bromo-6-methoxyl group-2-naphthyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF, with the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction; Get organic layer, steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[2-(5-bromo-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[2-(5-bromo-6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester; Feed dry hydrogen chloride and get indomethacin 2-[2-(5-bromo-6-methoxyl group-2-naphthyl) morpholinyl] carbethoxy hydrochloride; Yield 33%, fusing point: 225～227 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 2.36 (s, 3H, CH 3), 2.66 (br, 2H, C 4H 7NO 3,5-Ha), and 3.28～3.56 (m, 4H, NCH 2, C 4H 7NO 5-He, 3-He), 3.81 (s, 2H, OCH 2), 3.85 (s, 3H, indole ring CH 3O), 3.98 (br, 1H, C 4H 7NO 6-Ha), 4.04 (s, 3H, naphthalene nucleus CH 3O), 4.46 (br, 1H, C 4H 7NO 6-He), 4.71 (br, 2H, CH 2CO), 5.43 (br, 1H, C 4H 7NO 2-H), 6.68～8.22 (m, 12H, C 10H 5, C 6H 4, C 6H 3), 13.80 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 12 indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester vitriol
Indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester is dissolved in the ethanol, adds the sulfuric acid stirring reaction, gets indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester vitriol through aftertreatment.
Figure GSA00000080284500121
Embodiment 13 indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] the phosphatic preparation of ethyl ester
Figure GSA00000080284500122
Indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester is dissolved in the ethanol, adds the phosphoric acid stirring reaction, gets indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] acetophos hydrochlorate through aftertreatment.
The preparation of embodiment 14 indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester tosilate
Figure GSA00000080284500123
Indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester is dissolved in the ethanol, adds the tosic acid stirring reaction, gets indomethacin 2-[2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester tosilate through aftertreatment.
The preparation of embodiment 15 indomethacin 2-[3-methyl-2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500124
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol (3-methyl-6-methoxyl group-2-naphthyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF; With the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction gets organic layer; Steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[3-methyl-2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[3-methyl-2-(6-methoxyl group-2-naphthyl) morpholinyl] ethyl ester; Feed dry hydrogen chloride and get indomethacin 2-[3-methyl-2-(6-methoxyl group-2-naphthyl) morpholinyl] carbethoxy hydrochloride; Yield 22%, fusing point: 145～147 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 1.27 (d, J=6.4Hz, 3H, CH 3), 2.44 (s, 3H, CH 3), 2.72 (br, 1H, C 4H 7NO 3-H), 3.08 (br, 2H, NCH 2), 3.31 (d, J=11.2Hz, 1H, C 4H 7NO 5-Ha), 3.67 (br, 1H, C 4H 7NO 5-He), 3.77 (dd, J=10.4, J=2.0Hz, 1H, C 4H 7NO 6-Ha), 3.81 (s, 2H, OCH 2), 3.86 (s, 3H, indole ring CH 3O), 3.93 (s, 3H, naphthalene nucleus CH 3O), 4.46 (br, 1H, C 4H 7NO 6-He), 4.66 (s, 2H, CH 2CO), 5.01 (br, 2H, C 4H 7NO 2-H), 6.69～7.75 (m, 13H, C 10H 6, C 6H 4, C 6H 3), 13.47 (s, 1H, N-H).Meet constitutional features.
The preparation of embodiment 16 indomethacin 2-[3-methyl-2-(4-benzyloxy phenyl) morpholinyl] ethyl ester and hydrochloride thereof
Figure GSA00000080284500131
The indomethacin acyl chlorides that the dissolving of 8mL THF makes, the tetrahydrofuran solution of dropping 2mmol 3-methyl-2-(4-benzyloxy phenyl)-4-hydroxyethyl morpholine, the 1mL triethylamine is made acid binding agent; Stirring at room reaction 6h, reaction finishes, and filters; Filtrating is through the removal of solvent under reduced pressure THF; With the unnecessary indomethacin of 1.0mol/L sodium hydroxide solution flush away, ethyl acetate extraction gets organic layer; Steam and remove ETHYLE ACETATE, column chromatography gets indomethacin 2-[3-methyl-2-(4-benzyloxy phenyl) morpholinyl] ethyl ester.
With a small amount of anhydrous diethyl ether dissolving indomethacin 2-[3-methyl-2-(4-benzyloxy phenyl) morpholinyl] ethyl ester, feed dry hydrogen chloride and get indomethacin 2-[3-methyl-2-(4-benzyloxy phenyl) morpholinyl] carbethoxy hydrochloride, yield 17%, fusing point: 122～125 ℃.Proton nmr spectra structural characterization data: 1H NMR (CDCl 3, 400MHz), δ: 1.21 (br, 3H, CH 3), 2.43 (s, 3H, CH 3), 2.68 (br, 1H, C 4H 7NO 3-H), 2.95 (br, 2H, NCH 2), 3.15 (br, 1H, C 4H 7NO 5-Ha), 3.70 (br, 1H, C 4H 7NO 5-He), 3.83～3.86 (br, 5H, OCH 2, indole ring CH 3O), 3.93 (s, 1H, C 4H 7NO6-Ha), 4.41 (br, 1H, C 4H 7NO 6-He), 4.65 (s, 2H, CH 2CO), 4.82 (br, 1H, C 4H 7NO 2-H), 5.06 (s, 2H, PhCH 2O), 6.68～7.68 (m, 16H, C 6H 5, C 6H 4, C 6H 4, C 6H 3), 13.37 (s, 1H, N-H).Meet constitutional features.
Embodiment 17 Indometacin 2-arylmorpholine ethyls and hydrochloride thereof suppress active to people's cyclooxygenase-2 (COX-2)
Cyclo-oxygenase-1 (COX-1) and people's cyclooxygenase-2 (COX-2) model active suppression test of preferred compound indomethacin 2-of the present invention [2-(4-aminomethyl phenyl) morpholinyl] carbethoxy hydrochloride, indomethacin 2-[2-(4-ethylphenyl) morpholinyl] carbethoxy hydrochloride, indomethacin 2-[2-(4-p-methoxy-phenyl) morpholinyl] carbethoxy hydrochloride, indomethacin 2-[2-(4-isopropyl phenyl) morpholinyl] carbethoxy hydrochloride, indomethacin 2-[2-(4-butoxy phenyl) morpholinyl] carbethoxy hydrochloride and indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] carbethoxy hydrochloride are following:
1) experiment purpose: cyclo-oxygenase generates prostaglandin(PG) and oxyradical (ROS) through metabolism arachidonic acid (AA).Cyclo-oxygenase (COX-2) is one of key factor of inflammation incidence and development.Cyclo-oxygenase-1 (COX-1) is then mainly regulated physiological function.The COX-2 selective depressant avoids interference physiological function in anti-inflammatory, be the good target spot of anti-inflammatory treatment, and the suppressor factor that screens it has tangible application scenario.
2) test philosophy: COX-2 metabolism arachidonic acid generates prostaglandin(PG) and ROS.Measure R OS fluorescence or PGE2 generate, to confirm enzymic activity.
3) COX-1 and COX-2 are active detects
A. the acquisition of Turnover of Mouse Peritoneal Macrophages and cultivation
1ml/ only for C57BL/6J mouse peritoneal injection sodium thioglycollate substratum (preparation more than 1 month in advance, sterilization back room temperature keeps in Dark Place).Inject back 4 days with the mouse sacrificed by decapitation, drain blood, in 75% ethanol, soak 1～2min.Abdominal injection D-Hanks physiological buffer 6～8ml, fully liquid in the sucking-off abdominal cavity slowly after the massage repeats to wash the abdominal cavity 1 time again, merges the abdominal cavity washing lotion.The centrifugal 5min of 1000r/min, supernatant inclines.Add 1～2ml Tris-NH 4Cl solution shakes gently and treats brokenly to dilute the centrifugal 5min of 1000r/min with isopyknic D-Hanks physiological buffer immediately behind the red corpuscle, the supernatant that inclines, and with D-Hanks physiological buffer washing 2 times, cell is resuspended with RPMI 1640 substratum again.Measure cytoactive with trypan blue rejection method, the scavenger cell percentage is greater than 95% in the Giemsa staining inspection gained cell.
B.COX-1 is active to be detected
Peritoneal macrophage is pressed 1 * 10 9Cells/L concentration is inoculated in 48 orifice plates.37 ℃, 5%CO 2Adherent culture 2h.The substratum that inclines with D-Hanks physiological buffer flushing 2 times, is removed not attached cell, and every hole adds the RPMI1640 substratum that contains 5%NCS and presses column split and handle: 1. DMSO negative control group (control); 2. A23187 organizes (final concentration 1 μ mol.L -1); 3. A23187+I and II organize (5 μ mol.L -1); 4. A23187+Celecoxib organizes (1 μ mol.L -1).Every group 3 multiple hole, and repeat independent experiment 3 times.With above-mentioned 37 ℃ of Turnover of Mouse Peritoneal Macrophages and medicine or the solvents that is inoculated in 48 orifice plates, 5%CO 2Temperature is incubated 1h, and adding the A23187 final concentration again is 1 μ mol.L -1, 37 ℃, 5%CO 2Temperature is incubated 1h, collects supernatant, uses 125The 6-keto-PGF of I mark 1 αRadioimmunological kit is measured 6-keto-PGF in the cell culture supernatant 1 αContent.Make typical curve by test kit provider legal system, from typical curve, calculate respective concentration according to the testing sample measured value.
C.COX-2 is active to be detected
Peritoneal macrophage is pressed 1 * 10 9Cells/L concentration is inoculated in 48 orifice plates.37 ℃, 5%CO 2Adherent culture 2h.The substratum that inclines with D-Hanks physiological buffer flushing 2 times, is removed not attached cell, and every hole adds the RPMI1640 substratum that contains 5%NCS and presses column split and handle: 1. DMSO negative control group (control); 2. LPS organizes (final concentration 1mg/L); 3. LPS+I and II organize (10 μ mol.L -1); 4. LPS+celecoxib organizes (1 μ mol.L -1).With above-mentioned 37 ℃ of Turnover of Mouse Peritoneal Macrophages and medicine or the solvents that is inoculated in 48 orifice plates, 5%CO 2Temperature is incubated 1h, and adding the LPS final concentration again is 1mg/L, and 37 ℃, 5%CO 2Temperature is incubated 9h, collects supernatant, uses 3The PGE of H mark 2Radioimmunological kit is measured PGE in the cell culture supernatant 2Content.
4) test-results
A. the calculating of peritoneal macrophage inhibiting rate:
According to formula
Inhibiting rate (%)=(Cs-Ct)/(Cs-Cc) * 100%
The computerized compound is to COX-2 and the active restraining effect of COX-1.Wherein Cs, Ct and Cc represent PGE in LPS or A23187 group, testing compound group and the cellular control unit culture supernatant respectively 2Or 6-keto-PGF 1 αConcentration.
B.IC 50Value is calculated
Sample solution concentration logarithmic value and inhibiting rate linear regression utilize the computed in software sample to peritoneal macrophage half-inhibition concentration IC 50Value.Preferred compound Indometacin 2-arylmorpholine ethyl or its salt are for the IC of COX-2 and COX-1 50List table 1 in.
Table 1 preferred compound of the present invention is to the IC of COX-2 enzyme and COX-1 enzyme 50
Figure GSA00000080284500161
The active testing result shows that compound I of the present invention or II have good people's cyclooxygenase-2 (COX-2) and suppress active.Wherein, the activity of indomethacin 2-[2-(4-ethylphenyl) morpholinyl] carbethoxy hydrochloride and indomethacin 2-[2-(2,4-two chloro-5-fluorophenyls) morpholinyl] carbethoxy hydrochloride is strong than celecoxib.Compound shown in formula I or the formula II is used to prepare anti-inflammation and analgesic drugs, has no side effect.

Claims (3)

1. Indometacin 2-arylmorpholine ethyl (I) or its salt (II) is characterized in that it has following chemical structural formula:
Figure FSB00000557266200011
Wherein, R is selected from: hydrogen, C 1～C 4Alkyl; Ar is selected from: 2, and 4-two chloro-5-fluorophenyls, 4-aminomethyl phenyl, 4-ethylphenyl, 4-p-methoxy-phenyl or 4-isopropyl phenyl; HY is selected among the formula II: HCl, HBr, H 3PO 4, H 2SO 4, CH 3SO 3H or p-CH 3C 6H 4SO 3H.
2. the preparation method of the said Indometacin 2-arylmorpholine ethyl of claim 1 or its salt; It is characterized in that the indomethacin acyl chlorides is dissolved in the THF; Stir and drip 4-hydroxyethyl-2-aryl morpholine tetrahydrofuran solution down; Reaction finishes, and THF is reclaimed in distillation, obtains Indometacin 2-arylmorpholine ethyl (I); Indometacin 2-arylmorpholine ethyl is dissolved in anhydrous diethyl ether or the ethanol, feed dry HCl gas or with sour HY reaction, obtain Indometacin 2-arylmorpholine ethyl salt (II):
Wherein, the definition of Ar, R and HY according to claim 1.
3. the application of claim 1 described Indometacin 2-arylmorpholine base ethyl ester or its salt is characterized in that, compound shown in formula I or the formula II is as the application of preparation anti-inflammation and analgesic drugs.
CN2010101449965A 2010-04-13 2010-04-13 Indometacin 2-arylmorpholine ethyl, preparation method and application thereof Expired - Fee Related CN101812058B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101449965A CN101812058B (en) 2010-04-13 2010-04-13 Indometacin 2-arylmorpholine ethyl, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101449965A CN101812058B (en) 2010-04-13 2010-04-13 Indometacin 2-arylmorpholine ethyl, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN101812058A CN101812058A (en) 2010-08-25
CN101812058B true CN101812058B (en) 2012-03-21

Family

ID=42619437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101449965A Expired - Fee Related CN101812058B (en) 2010-04-13 2010-04-13 Indometacin 2-arylmorpholine ethyl, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN101812058B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077969A1 (en) * 2009-08-31 2011-10-05 Abbott Healthcare Products Bv DERIVATIVES OF (TIO) MORFOLINA COMOMODULADORES DE S1P
TWI543984B (en) 2010-07-09 2016-08-01 艾伯維公司 Spiro-piperidine derivatives as s1p modulators
TWI522361B (en) 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivatives as s1p modulators
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
CN102940639A (en) * 2012-11-12 2013-02-27 湖南大学 Application of indometacin2-aryl morpholine ethyl ester in preparing medicine capable of resisting breast cancer
CN114728982A (en) 2019-10-31 2022-07-08 逃逸生物有限公司 Solid forms of S1P-receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100427475C (en) * 2006-11-30 2008-10-22 华南理工大学 Naproxen-2-aryl morpholine ethyl ester and its preparation method and uses

Also Published As

Publication number Publication date
CN101812058A (en) 2010-08-25

Similar Documents

Publication Publication Date Title
CN101812058B (en) Indometacin 2-arylmorpholine ethyl, preparation method and application thereof
Smith et al. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib
Paramashivappa et al. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors
Odlo et al. 1, 5-Disubstituted 1, 2, 3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Rathore et al. In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings
EP2310371B1 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
Tang et al. Discovery of novel sesquistilbene indanone analogues as potent anti-inflammatory agents
Xie et al. Unexpected synthesis of 2, 4, 5-trisubstituted oxazoles via a tandem aza-Wittig/Michael/isomerization reaction of vinyliminophosphorane
EP3653613B1 (en) 1,3-di-substituted ketene compound and application thereof
CA2658625A1 (en) Substituted imidazolone derivatives, preparation and uses
Velázquez et al. Synthesis and biological evaluation of 3, 4-diphenyl-1, 2, 5-oxadiazole-2-oxides and 3, 4-diphenyl-1, 2, 5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents
De Filippis et al. Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism
Hanessian et al. Stereocontrolled total synthesis of an annonacin A-type acetogenin: pseudoannonacin A?
Shaikh et al. An efficient solvent-free synthesis of imidazolines and benzimidazoles using K 4 [Fe (CN) 6] catalysis
Kasuga et al. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists
CN111423394B (en) Synthesis method of 1,3, 4-oxadiazole heterocyclic compound
CN101492426A (en) Thiazole schiff base containing nitryl, preparation and uses thereof
US7989450B2 (en) Functionalized diarylisoxazoles inhibitors of ciclooxygenase
AU2014237600B2 (en) Bicyclic pyrrole derivatives useful as agonists of GPR120
Wang et al. Construction of N-Boc monofluoromethyl aryl sulfones via Mannich reaction of α-amido sulfones with trifluoromethyl α-fluorinated arylsulfonyl gem-diols
Pirat et al. Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression
CN115716822A (en) Application of benzimidazolyl isoxazole compound in preparation of medicines related to multiple myeloma
Prasad et al. An efficient and straight forward synthesis of (5S)-1-benzyl-5-(1H-imidazol-1-ylmethyl)-2-pyrrolidinone (MM1): a novel antihypertensive agent
Adnan et al. Design, Synthesis, and Acute Anti-inflammatory Assessment of New 2-methyl Benzoimidazole Derivatives Having 4-Thiazolidinone Nucleus
CN107382892A (en) A kind of preparation technology of the nitro isoxazole compound of 3 aryl 4

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120321

Termination date: 20150413

EXPY Termination of patent right or utility model